Everything below concerns fatty acid oxidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
=== Sources === Cleveland Clinic. "LADA Diabetes." Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/lada-diabetes. Accessed 9 Apr. 2026. Diabetes UK. "Latent Autoimmune Diabetes (LADA)." Diabetes UK, https://www.diabetes.org.uk/about-diabetes/other-types-of-diabetes/latent-autoimmune-diabetes. Accessed 9 Apr. 2026. Eisenbarth, George S., ed. (2010). Immunoendocrinology: Scientific and Clinical Aspects. Contemporary Endocrinology. Humana Press. ISBN 978-1-603-27477-7. Flynn, John A.; Michael J. Choi; L. Dwight Wooster, eds. (2013). Oxford American Handbook of Clinical Medicine. Oxford American Handbooks in Medicine. Oxford University Press. ISBN 978-0-195-18849-3. HealthNormal. "Latent Autoimmune Diabetes in Adults." HealthNormal, https://www.healthnormal.com/latent-autoimmune-diabetes-in-adults/. Accessed 9 Apr. 2026. "Latent Autoimmune Diabetes in Adults: Current Status and New Horizons." SN Comprehensive Clinical Medicine, 2025, https://link.springer.com/article/10.1007/s42399-025-02003-1. Accessed 9 Apr. 2026. "Management of Latent Autoimmune Diabetes in Adults." Diabetes, vol. 69, no. 10, 2020, https://diabetesjournals.org/diabetes/article/69/10/2037/16062. Accessed 9 Apr. 2026. Munden, Julie, ed. (2006). Diabetes Mellitus: A Guide to Patient Care. Lippincott Williams & Wilkins. ISBN 978-1-58255-732-8. Haskins, Jacqueline. Kickass Healthy LADA: How to Thrive with Latent Autoimmune Diabetes in Adults. Hachette Go (2023). ISBN 9780306830730.
=== Josh Thomas and Lachlan Keeffe === Lachlan Keeffe (drafted to Collingwood in 2008) and Josh Thomas (drafted to Collingwood in 2009) are the most recent players to breach the anti-doping code. They both tested positive for clenbuterol which led to a 2-year ban as well as a $50,000 fine. The banned substance was detected in their systems after taking illicit drugs during a night out. Both players were banned from playing AFL for 2 years and were delisted by the Collingwood Football Club, before being redrafted by Collingwood in the 2016 Rookie Draft.
=== FastPP === In fast parallel proteolysis the researcher adds a thermostable protease (thermolysin) and takes out samples in parallel upon heating in a thermal gradient cycler. Optionally, for instance for proteins expressed at low levels, a western blot is then run to determine at what temperature a protein becomes degraded. For pure or highly enriched proteins, direct SDS-PAGE detection is possible facilitating Commassie-fluorescence based direct quantification. FastPP exploits that proteins become increasingly susceptible to proteolysis when unfolded and that thermolysin cleaves at hydrophobic residues which are typically found in the core of proteins. To reduce the workload, western blots could be replaced by SDS-PAGE gel polyhistidine-tag staining, provided that the protein has such a tag and is expressed in adequate amounts. FastPP can be used on unpurified, complex mixtures of proteins and proteins fused with other proteins, such as GST or GFP, as long as the sequence that is the target of the western blot, e.g., His-tag, is directly linked to the protein of interest. However, commercially available thermolysin is dependent on calcium ions for activity and denatures itself just above 85 degrees Celsius. So calcium must be present and calcium chelators absent in the buffer - other compounds that interfere with the function (such as high concentrations of detergents) of the protease could also be problematic. FASTpp has also been used to monitor binding-coupled folding of intrinsically disordered proteins (IDPs).
=== North America === Accium BioSciences at Swedish Medical Center Cherry Hill, Seattle, WA André E. Lalonde Accelerator Mass Spectrometry Laboratory (AEL AMS) at the University of Ottawa in Ottawa, Canada Beta Analytic Accelerator Mass Spectrometry Facility in Miami, Florida Center for Accelerator Mass Spectrometry (CAMS) at the Lawrence Livermore National Laboratory Center for Applied Isotope Studies (CAIS) at University of Georgia. DirectAMS (D-AMS) radiocarbon labs in Bothell, WA & Seattle, WA Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan Institute for Structure and Nuclear Astrophysics, The University of Notre Dame, Notre Dame, Indiana Institute of Energy and the Environment Radiocarbon Laboratory at the Pennsylvania State University, University Park, Pennsylvania MegaSIMS at the University of California, Los Angeles in Los Angeles, CA National Ocean Sciences Accelerator Mass Spectrometry (NOSAMS) Facility at Woods Hole Oceanographic Institution NSF - Arizona Accelerator Mass Spectrometry (AMS) Laboratory Pharmaron ABS, Inc. in Germantown, Maryland Purdue Rare Isotope Measurement Laboratory at Purdue University in West Lafayette, Indiana Trace Element Accelerator Mass Spectrometer (TEAMS) at the Naval Research Laboratory in Washington, DC W.M. Keck Carbon Cycle Accelerator Mass Spectrometry (KCCAMS) Facility at the University of California, Irvine
== Use and effects == The psychoactive dose range of nutmeg has been reported to be 5 to 30 grams (equivalent to about 0.4–4.5 grams of volatile oil) or approximately one to three nutmegs orally, with a common dose being around 15 to 20 grams of nutmeg. Its onset is delayed with a range of 1 to 8 hours and its duration is 9 to 24 hours, but with residual effects lasting up to 48 to 60 hours or several days. Insufflation is a rare route of administration, but might result in more rapid onset. The effects of nutmeg have been reported to include drowsiness, stupor, delirium, disorientation, time dilation, dream-like state or "dream pictures", feelings of unreality, distortion of time and space, and initial stimulation followed by subsequent tranquilization. In other reports, the effects included euphoria, peace of mind, excitement, silly feelings and giggling, laughing fits, pleasant and dreamy visions, trance-like state, feeling like everything is in slow motion, drunkenness, perceptual distortion, mental disruption, loss of memory, being "wacked out of your head, sort of", and anxiety. Visual hallucinations are said to be infrequent. It is described as not being especially pleasant and as being highly unpleasant for most users due to pronounced side effects. Nutmeg has been compared to cannabis intoxication by many users. Other authors have described it as producing anticholinergic-like deliriant symptoms.
Sources: en.wikipedia.org
In August 2011, there was a 12-week double-blind, placebo controlled phase 2 trial that focused on elderly men and postmenopausal women which concluded that enobosarm showed statistically significant improvements in total lean body mass and physical function without apparent adverse effects on hair growth or sebum production. In August 2013, GTx announced that enobosarm had failed in two phase 3 clinical trials to treat wasting in people with lung cancer. The company had invested around $35 million in the development of the drug. The company said at that time that it planned to pursue approval of enobosarm in Europe; the company was also still developing GTx-758, a nonsteroidal estrogen, for castration-resistant prostate cancer. As of 2018, enobosarm was the only SARM to have reached or completed phase 3 clinical trials. In 2016, GTx began phase 2 trials, to see if enobosarm might be effective to treat stress urinary incontinence in women. In 2018, GTx announced the phase 2 trials on the effectiveness of enobosarm for stress urinary incontinence in women failed to achieve its primary endpoint in the ASTRID Trial. By September 2023, development of enobosarm for stress urinary incontinence had been discontinued. In 2022, the FDA granted fast tract designation to enobosarm in AR+, ER+, HER2- metastatic breast cancer. In January 2024, Veru Inc. submitted an Investigational New Drug application to the FDA of enobosarm for prevention of muscle loss and augmentation of fat loss in combination with glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide for weight loss.
Routine blood tests often discover anemia. A sufficiently low hemoglobin by definition makes the diagnosis of anemia, and a low hematocrit value is also characteristic of anemia. Further studies will be undertaken to determine the cause of anemia. If the anemia is due to iron deficiency, one of the first abnormal values to be noted on a complete blood count, as the body's iron stores begin to be depleted, will be a high red blood cell distribution width, reflecting an increased variability in the size of red blood cells. A low mean corpuscular volume also appears during the course of body iron depletion. It indicates a high number of abnormally small red blood cells. A low mean corpuscular volume, a low mean corpuscular hemoglobin or mean corpuscular hemoglobin concentration, and the corresponding appearance of red blood cells on visual examination of a peripheral blood smear narrows the problem to a microcytic anemia (literally, a small red blood cell anemia). The blood smear of a person with iron-deficiency anemia shows many hypochromic (pale, relatively colorless) and small red blood cells. It may also show poikilocytosis (variation in shape) and anisocytosis (variation in size). With more severe iron-deficiency anemia, the peripheral blood smear may show hypochromic, pencil-shaped cells and, occasionally, small numbers of nucleated red blood cells. The platelet count may be slightly above the high limit of normal in iron-deficiency anemia (termed a mild thrombocytosis), but severe cases can present with thrombocytopenia (low platelet count).
18 November At the 2024 G20 Rio de Janeiro summit, Starmer holds talks with Chinese president Xi Jimping and emphasises the importance of a "strong UK–China relationship" for both countries. Consultancy firm Cornwall Insight forecasts a slight rise in the energy price cap in January, and says that high energy prices will be the "new normal". Thames Valley Police confirm that two vehicles were stolen from a farm on the estate surrounding Windsor Castle in October. The King was not in residence at the time. Research by BBC News has discovered that waiting lists for gynaecology appointments across the UK have more than doubled since February 2020, with 755,046 people currently awaiting treatment. A technical issue leaves a number of British Airways flights stranded at multiple locations as they are unable to take off. The problem is resolved by the following day. 19 November More than 200 schools are closed as snow brings disruption to large areas of the UK. Motorists and commuters are warned of disruption as three yellow warnings for snow and ice remain in effect. Zoe Ball announces that she will step down as presenter of Radio 2's Breakfast Show in December, with Scott Mills replacing her. Several thousand people attend a protest in London over inheritance tax increases for farmers, announced in the October budget.
== Signs and symptoms == In their early stages, soft-tissue sarcomas usually do not cause symptoms. Because soft tissue is relatively elastic, tumors can grow rather large, pushing aside normal tissue, before they are felt or cause any problems. The first noticeable symptom is usually a painless lump or swelling. As the tumor grows, it may cause other symptoms, such as pain or soreness, as it presses against nearby nerves and muscles. If in the abdomen it can cause abdominal pains commonly mistaken for menstrual cramps, indigestion, or cause constipation.
Sources: en.wikipedia.org
=== Homologues === Each domain of life (Eubacteria, Archaea, and Eukaryotes) have different release factors associated with the termination of translation. Eubacteria have multiple release factor to recognize stop codons whereas Eukaryotes (eRF1) and Archaea (aRF1) have only one protein to recognize all three stop codons. The structural and functional differences between Eubacteria release factors and Archean/Eukaryotic are believed to have evolved separately with a divergence point early on. The functional similarities between eRF1 and aRF1 has led to theories of a common ancestor where both proteins evolved from. However, very little has been studied about Archean release factors. In prokaryotes, the release factors are characterized in 2 classes. Class 1 release factors recognize stop codon, and class 2 release factors stimulate hydrolysis by GTPase activity. However, prokaryotes don't have a single protein to recognize all the stop codons. The stop codon UAG is decoded by Release Factor 1 (RF1) and UGA is decoded by Release Factor 2. The final stop codon UAA is decoded by both RF1 and RF2. In Eukaryotes, eRF1 recognizes all three stop codons. Although there is a distinct difference between prokaryotic codon recognition and Archean/Eukaryotic codon recognition, the functionality of the catalytic site is conserved throughout all domains. Each domain has the critical GGQ site to promote peptide hydrolysis.
When the reagent is methane, the predominant reaction is proton transfer M + CH5+ → (MH)+ + CH4. When the reagent is ammonium, the predominant reaction is proton transfer M + NH4+ → (MH)+ + NH3. When the reagent is isobutane, the reaction may be proton transfer M + (CH3)3C+ → (MH)+ + (CH3)2C=CH2 or adduct formation M + (CH3)3C+ → (M · C(CH3)3)+. CI can also produce negatively charged analyte ions by proton abstraction or adduct formation. For example, ionized NF3 contains F−, which abstracts proton.
In Lebanese nationalist narratives, Fakhr-al-Din II is celebrated as establishing a sort of Druzes–Maronite condominium that is often portrayed as the embryo of Lebanese statehood and national identity. Nationalist narratives by Lebanese Druze and Maronites agree on Fakhr al-Din's "decisive influence and contribution to Lebanon's history", according to the historian Yusri Hazran, though they differ significantly in determining the Emir's motives and the historic significance of his rule. Druze authors describe him as the ideal ruler who strove to achieve strong domestic unity, build a prosperous economy, and politically free Lebanon from Ottoman oppression. Making the case that the Ma'nids worked toward Lebanon's integration into the Arab regional environment, the Druze authors generally de-emphasize his relations with Europe and portray his drive for autonomy as the first forerunning of the Arab nationalist movement. On the other hand, Maronite authors viewed the legacy of Fakhr al-Din as one of isolation from the Arab–Islamic milieu. Fakhr al-Din himself has been adopted by a number of Maronite nationalists as a member of the religious group, citing the refuge he may have taken with the Khazens in Keserwan during his adolescence, or claiming that he had embraced Christianity at his deathbed. According to the historian Christopher Stone, Fakhr al-Din was used by the Rahbani brothers in their Lebanese nationalist play, The Days of Fakhr al-Din, as "a perfect historical predecessor for Lebanon's Christian nationalism of the twentieth century".
In India, Ayurvedic medicine has quite complex formulas with 30 or more ingredients, including a sizable number of ingredients that have undergone "alchemical processing", chosen to balance dosha. In Ladakh, Lahul-Spiti, and Tibet, the Tibetan Medical System is prevalent, also called the "Amichi Medical System". Over 337 species of medicinal plants have been documented by C.P. Kala. Those are used by Amchis, the practitioners of this medical system. The Indian book, Vedas, mentions treatment of diseases with plants.
The two substrates of this enzyme are indan-1-ol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 1-indanone, reduced NADH and a proton. The enzyme can use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is indan-1-ol:NAD(P)+ 1-oxidoreductase.
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.